For decades, male birth control has offered a remarkably short menu: condoms, vasectomy, withdrawal, or a heartfelt promise to “be careful.” RISUG could eventually add a long-acting, non-hormonal option that does not require daily attention or permanently cutting the vas deferens.
RISUG stands for Reversible Inhibition of Sperm Under Guidance. Developed in India, this experimental contraceptive involves injecting a polymer into the tubes that carry sperm. Research suggests that one procedure may provide years of contraception without suppressing testosterone. However, the word reversible comes with an important asterisk: reversal has worked in animal research, but reliable restoration of fertility has not yet been adequately demonstrated in humans.
RISUG is also not an approved or routinely available birth-control method in the United States. It remains a promising subject of researchnot something a person can currently order during a quick visit to the neighborhood urologist.
What Is RISUG Male Birth Control?
RISUG is an investigational, non-hormonal male contraceptive designed to act inside the vas deferens. These two narrow tubes carry sperm from the epididymis toward the urethra during ejaculation.
The RISUG formulation contains a copolymer called styrene maleic anhydride, commonly abbreviated as SMA, dissolved in dimethyl sulfoxide, or DMSO. A trained clinician injects the material into each vas deferens using a minimally invasive technique and local anesthesia.
Unlike vasectomy, the procedure is not intended to cut, tie, seal, or remove a section of the vas deferens. Instead, the polymer settles along the inner surface of the tubes, where it interferes with sperm as they pass through.
How Does RISUG Work?
A localized barrier inside the vas deferens
RISUG is often described as an injectable sperm-blocking gel, but “plug” is not a complete explanation. The polymer can partially restrict sperm movement, yet laboratory studies suggest that it also changes the local chemical and electrical environment inside the vas deferens.
Sperm that encounter the polymer may develop damage to their membranes, tails, heads, or acrosomes. The acrosome contains enzymes that help a sperm penetrate an egg. If that structure is disrupted, the sperm may remain visible in a semen sample while being unable to fertilize an egg.
No intentional suppression of testosterone
Hormonal male contraceptives generally attempt to reduce sperm production by altering signals involving testosterone and other reproductive hormones. RISUG takes a different route: the testicles may continue producing sperm and hormones, while the intervention acts farther down the reproductive tract.
Because it is localized, RISUG is not expected to intentionally reduce testosterone, libido, erections, orgasm, or semen production. Most semen volume comes from the prostate and seminal vesicles rather than the testicles, so ejaculation should still occur. Nevertheless, larger controlled studies are required before researchers can confidently describe every long-term effect.
What Happens During the RISUG Procedure?
The clinical procedure investigated in India resembles some steps used during a no-scalpel vasectomy:
- The scrotal area is cleaned, and a local anesthetic is administered.
- The clinician locates and temporarily holds one vas deferens near the skin.
- A small puncture or opening provides access to the tube.
- A measured dose of the SMA-DMSO formulation is injected into the vas deferens.
- The process is repeated on the opposite side.
The injection is aimed at the vas deferensnot the penis or testicle, despite headlines that sometimes make the procedure sound like a scene from a medical horror comedy.
RISUG should not be assumed to work immediately. Clinical research has used follow-up semen analyses to determine whether sperm counts have fallen sufficiently or whether remaining sperm show disabling abnormalities. Until effectiveness is confirmed, another contraceptive method would be necessary.
What Does the Research Show?
Results from clinical studies in India
RISUG has progressed further in human research than many experimental male contraceptives. Early and mid-stage studies reported prolonged contraceptive effects following a single administration. A multicenter Phase III study published in 2023 enrolled 303 healthy, sexually active married men between 25 and 40 years old, along with their partners.
The study reported 97.3% efficacy based on achieving azoospermia, meaning no sperm detected in semen, and 99.02% efficacy based on pregnancy prevention. No serious treatment-related adverse effect was reported. Temporary scrotal enlargement, discomfort, low-grade fever, or swelling occurred in some participants and generally resolved.
Those numbers are encouraging, but they require context. The trial was open-label and nonrandomized, meaning participants and researchers knew what treatment was given, and there was no randomized control group. Participants had already approached family-planning or surgical clinics for vasectomy-related care, so they may not represent all potential users.
Azoospermia was not achieved uniformly or immediately. Some men developed very low sperm counts or abnormal sperm before eventually reaching azoospermia, while a small proportion experienced method or administration failure. Pregnancy prevention data can also be affected by sexual frequency, partner fertility, follow-up duration, and reporting.
Promising evidence is not the same as approval
A successful study does not automatically place a treatment on pharmacy shelves. Regulators need consistent manufacturing standards, well-designed safety data, reliable administration procedures, long-term monitoring, and evidence that benefits outweigh risks.
As of July 2026, RISUG is not approved by the U.S. Food and Drug Administration and is not available as routine male birth control in the United States. Related vas-occlusive polymer technologies have entered development under names such as Vasalgel and Plan A, but these should not be treated as approved versions of RISUG. Formulations, delivery systems, studies, and regulatory pathways may differ.
Can RISUG Really Be Reversed?
Reversibility is the feature that makes RISUG especially excitingand the feature that deserves the most caution.
In animal studies, researchers have attempted reversal by flushing the vas deferens with substances such as sodium bicarbonate or DMSO. Experiments in rodents and primates have reported removal or disruption of the polymer, reopening of the reproductive tract, recovery of sperm in semen, and restoration of fertility.
That does not yet prove dependable human reversibility. Published human evidence has not established how often fertility returns, how long recovery takes, whether reversal works after many years, or whether children conceived after reversal face any additional risk.
Until rigorous human reversal studies answer those questions, a prospective user should not regard RISUG as casually reversible. If it eventually becomes available before human reversibility is firmly established, counseling may need to resemble counseling for permanent contraception.
Potential Benefits of RISUG
- Long-acting contraception: One administration may remain effective for years, although the exact duration requires confirmation.
- Non-hormonal action: The method does not depend on routinely suppressing reproductive hormones.
- No daily maintenance: Users would not need to remember a pill, apply a gel, or prepare a method before every sexual encounter.
- Localized treatment: The polymer is placed inside the vas deferens rather than distributed throughout the body as a systemic medication.
- Shared contraceptive responsibility: RISUG could allow more men to take an active, long-term role in preventing pregnancy.
- Possible reversibility: Animal research supports the concept, although human proof remains incomplete.
Risks and Unanswered Questions
Short-term reactions reported in studies have included scrotal swelling, mild pain, temporary enlargement, and low-grade fever. Any procedure involving the vas deferens could theoretically cause infection, bleeding, inflammation, injury, chronic discomfort, scar tissue, or an unsuccessful injection.
Important unanswered questions include:
- How safe is the polymer after 10, 15, or more years?
- Can clinicians deliver the correct dose consistently in everyday practice?
- Which semen-test result reliably confirms contraceptive protection?
- How often does the method fail because of anatomy or injection technique?
- Can fertility be restored predictably in humans?
- What happens if only one vas deferens is adequately treated?
- How does RISUG perform in larger and more diverse populations?
Another limitation is simple but crucial: RISUG is intended to prevent pregnancy, not sexually transmitted infections. Condoms would still be needed to reduce the risk of HIV and other STIs. A polymer in the vas deferens may have scientific superpowers, but it does not create an invisible force field around someone’s dating life.
RISUG vs. Condoms, Vasectomy, and Hormonal Methods
| Method | How It Works | Duration | Key Limitation |
|---|---|---|---|
| RISUG | Polymer injected into the vas deferens interferes with sperm | Potentially several years | Experimental; human reversibility is unproven |
| External condom | Barrier keeps semen from entering a partner’s body | One sexual act | Must be used correctly every time |
| Vasectomy | Vas deferens are divided or sealed | Permanent | Reversal is costly and not guaranteed |
| Experimental hormonal contraception | Hormones suppress sperm production | Depends on the formulation | Still under study; may cause systemic effects |
| Withdrawal | Penis is withdrawn before ejaculation | One sexual act | Highly dependent on timing and consistent use |
Experiences Related to RISUG: What the Patient Journey May Feel Like
Because RISUG is not in routine U.S. clinical use, authentic consumer experiences are limited largely to research participants. Online accounts should be approached carefully: some discuss related polymer technologies, while others repeat dramatic headlines without distinguishing a human trial from an animal experiment.
Before the procedure
An evidence-based RISUG experience would begin with counseling, a medical history, physical examination, and fertility discussion. A clinician would explain that the method is investigational and that reversal has not been proven in humans. The patient might provide semen samples so researchers can document sperm count, movement, and shape before treatment.
This conversation could feel more serious than selecting condoms because it concerns a long-acting procedure. A man who definitely wants children soon would have a different risk calculation from someone who has completed his family. Discussing sperm banking could be reasonable in a research setting, especially while human reversal remains uncertain.
During and immediately after treatment
The patient would be awake under local anesthesia. He might feel the initial anesthetic sting, pressure as the vas deferens is isolated, and brief discomfort during injection. The procedure involves the scrotal area, so nobody is likely to list it among their favorite Tuesday activities. Still, it is designed to avoid major surgery and general anesthesia.
Afterward, temporary tenderness or swelling may make supportive underwear, reduced activity, and clinician-approved pain relief useful. Research reports describe mainly mild, short-lived reactions, but an individual with increasing pain, fever, drainage, major swelling, or skin discoloration would need prompt medical evaluation.
The waiting period
The psychologically awkward part may be waiting for confirmation that the treatment works. As with vasectomy, a patient should not interpret “procedure completed” as “contraception confirmed.” Follow-up semen tests would be essential, and condoms or another reliable method would remain necessary until the research team provided clear guidance.
For couples, this period would require honest communication. One partner might feel optimistic about sharing contraceptive responsibility, while the other might remain understandably cautious about relying on an experimental method. A laboratory result is more dependable than enthusiasm, confidence, or a celebratory social-media post.
Living with long-acting male contraception
If follow-up testing confirmed contraceptive effectiveness, daily life might change very little. RISUG is not designed to alter erections, orgasm, ejaculation, testosterone, or sexual desire. There would be no daily pill and no contraceptive device to handle before sex.
That convenience could be the method’s most meaningful advantage. A reliable long-acting male contraceptive might reduce pressure on partners who experience side effects from hormonal contraception or cannot use certain methods for medical reasons. However, condom use would remain important whenever STI protection is needed.
When plans change
The most challenging experience could arise if a user later wanted biological children. Animal studies make reversal scientifically plausible, but a human patient could not responsibly assume that fertility would return quicklyor at all. Recovery would likely require another procedure, repeated semen analyses, and time for sperm parameters to improve.
This uncertainty explains why RISUG is both fascinating and unfinished. It offers a glimpse of contraception that could be long-lasting, non-hormonal, and controlled by men, yet its real-world value depends on proving more than pregnancy prevention. Researchers must also demonstrate consistent administration, durable safety, practical monitoring, and dependable human reversibility.
Conclusion
RISUG is one of the most advanced experimental approaches to non-hormonal male birth control. By placing an SMA-based polymer inside the vas deferens, it aims to disable or obstruct sperm without suppressing testosterone. Indian clinical studies have reported encouraging pregnancy-prevention rates and no serious treatment-related safety signal, but important limitations remain.
Most importantly, RISUG is not FDA-approved, is not routinely available in the United States, does not protect against STIs, and has not yet demonstrated reliable reversal in humans. Its future will depend on stronger controlled trials, long-term monitoring, standardized manufacturing, regulatory review, and convincing fertility-restoration data.
Note: This article is for general educational purposes and does not replace medical advice. RISUG remains investigational. Do not seek unregulated injections or attempt any form of self-administration; discuss approved contraceptive options with a qualified healthcare professional.
